UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 226, 2026

LOGO

VIRIDIAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36483

47-1187261

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

221 Crescent Street, Suite 103A

Waltham, MA

02453

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 272-4600

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.01 par value

VRDN

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 57.0701 ~~Submission~~Regulation ofFD ~~Matters to a Vote of Security Holders.~~Disclosure

On June 226, 2026, Viridian Therapeutics, Inc. (the “Company”) ~~held~~issued ~~its~~a ~~2026~~press ~~Annual~~release ~~Meeting~~announcing ofthat ~~Stockholders (~~the ~~“Annual~~U.S. ~~Meeting”)~~Food atand ~~which~~Drug ~~holders~~Administration of (the ~~Company’s~~“FDA”) ~~common~~has ~~stock~~approved asLumvoa™ of(veligrotug-vvze) for the ~~close~~treatment of ~~business~~thyroid oneye ~~April 7,~~disease ~~2026~~ (~~the~~ “~~Record Date~~TED”) ~~were~~regardless ~~entitled~~of toactivity ~~vote~~or duration. AsA copy of the ~~close~~press ofrelease ~~business~~is onfurnished ~~the~~as ~~Record~~Exhibit ~~Date,~~99.1 ~~103,071,889~~to ~~shares~~this ofCurrent ~~the~~Report ~~Company’s~~on ~~common~~Form ~~stock~~8-K ~~were~~and ~~issued~~is ~~and~~incorporated ~~outstanding~~herein by reference.

AtThe information in this Item 7.01 and in Exhibit 99.1 to this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the ~~Annual~~Exchange ~~Meeting~~Act, ~~each~~or ofotherwise subject to the ~~Company’s~~liabilities ~~director~~of ~~nominees~~that ~~was~~section, ~~elected~~nor ~~and~~shall it be deemed incorporated by reference in any filing under the ~~other~~Exchange ~~proposals~~Act ~~voted~~or onthe ~~were~~Securities ~~approved.~~Act, ~~The~~regardless ~~final~~of ~~voting~~any ~~results~~general ~~are~~incorporation language in such filing, except as shall be expressly set forth ~~below:~~by specific reference in such filing.

1Item 8.01 ~~Election~~Other ~~of the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders:~~ Events

	For		Withheld		Broker Non-Votes
Tomas Kiselak		72,363,500		14,475,646		6,733,104
Jennifer K. Moses		86,378,842		460,304		6,733,104

On June 26, 2026, the Company announced that the FDA has approved Lumvoa^™ (veligrotug-vvze) for the treatment of TED regardless of activity or duration. Lumvoa is the first approved treatment for TED with labeling that includes data for both active and chronic TED. Viridian plans to launch Lumvoa immediately.

2This Current Report on Form 8-K contains forward-looking statements, including, without limitation, statements regarding the Company’s plans to launch Lumvoa immediately. ~~Ratification~~Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the ~~selection~~Company’s current beliefs, expectations, and assumptions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of ~~KPMG~~any ~~LLP~~such asforward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to risks and uncertainties identified in the Company’s ~~independent~~filings ~~registered~~with ~~public~~the ~~accounting~~SEC, ~~firm~~including ~~for~~those risks set forth under the ~~fiscal~~caption ~~year~~“Risk ~~ending~~Factors” ~~December~~in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026:, filed with the SEC on May 5, 2026, and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company nor any of its affiliates, advisors or representatives undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

For		Against		Abstentions		Broker Non-Votes
92,866,008		512,582		193,660		—

Item 9.01

Financial Statements and Exhibits.

3(d) Exhibits. ~~Approval, on an advisory basis, of the compensation of the Company’s named executive officers:~~

For	Against	Abstentions	Broker Non-Votes
99.1	Press Release, dated June 26, 2026
83,512,086	3,113,724	213,336	6,733,104
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

4. Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers:

1 Year		2 Years		3 Years		Abstain
86,084,347		29,762		517,682		207,355

As a result of the foregoing vote, the Company’s Board of Directors has determined that the Company will conduct a non-binding advisory vote on the compensation of the Company’s named executive officers every year.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Viridian Therapeutics, Inc.

Date: June 3, 2026

/s/ Stephen Mahoney

Date: June 29, 2026

/s/ Stephen Mahoney

Stephen Mahoney

President and Chief Executive Officer

Filing Compare · Viridian Therapeutics, Inc.\DE